Preventive Effect of Rifampicin on Dementia

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K07488
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
• Principal Investigator: Kameyama Masashi 地方独立行政法人東京都健康長寿医療センター(東京都健康長寿医療センター研究所), 東京都健康長寿医療センター研究所, 研究員 (40773445)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: アルツハイマー病 / 認知症 / 人工知能

Outline of Final Research Achievements

Distinguishing Alzheimer's disease (AD) from other dementia is crucial for the future use of rifampicin. We have tried comparison of medial temporal lobe atrophy by MRI and amyloid PET for AD discrimination, distinguishing DLB, AD, and normal by perfusion SPECT and FDG PET images with AI, fractal analysis of Dopamine transporter SPECT, proposal of a new quantification method of cerebral blood flow, examination of reference region of amyloid PET by simulation, detection of degeneration by [18F]THK5351 PET, and screening of cognitive decline by facial complexion using AI.

Free Research Field

核医学

Academic Significance and Societal Importance of the Research Achievements

顔写真をAIが認知機能低下を見分けたことは、将来、AIを用いて顔で認知機能低下をスクリーニングすることができるようになるかもしれないという可能性を示しており、新聞などに取り上げられ、大きな反響があった。